Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

Names Gerald Orehostky as vice president of quality and regulatory operations

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Goodwin Biotechnology has appointed Gerald Orehostky as vice president, quality and regulatory. As a full GMP, FDA-registered and inspected biopharmaceuticals contract development and manufacturing organization (CDMO), Goodwin has continued its expansion to add commercial cGMP solutions to augment its offering of a fully integrated Single Source Solution from cell line development, process development including bioconjugation, scale-up, cGMP contract manufacturing and aseptic fill/finish of mammalian cell-culture derived life-saving monoclonal antibodies, recombinant proteins, vaccines, and antibody drug conjugates (ADCs).
 
“Jerry has more than 30 years of broad experience in quality systems, regulatory affairs, regulatory compliance, quality assurance, product development and commercial operations in biologics, bioconjugation, and other therapeutic areas,” said Karl Pinto, chief executive officer, Goodwin Biotechnology. “His extensive experience and, in-depth functional proficiency in quality assurance and regulatory affairs from early stage to commercial products will help guide Goodwin as we continue our expansion plans to continue our nearly 30-year legacy of servicing our clients in bringing their products into, and through the clinic with our unmatched service, flexibility, and quality. We are now transcending the clinic and taking the company into commercial manufacturing, and Jerry’s leadership will be instrumental towards this endeavor.”
 
Previously, Mr. Orehostky held leadership positions within regulatory affairs and quality operations at companies such as Actinium Pharmaceuticals, Antares Pharma, Discovery Laboratories, Palatin Technologies, Schering-Plough, Vivus, and Interferon Sciences.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics